Antineutrophil Cytoplasmic Antibodies in Patients with Idiopathic Inflammatory-Demyelinating Diseases

被引:9
|
作者
Long, Youming
Zheng, Yangbo
Chen, Mengyu
Zhang, Bin
Gao, Cong [1 ,2 ,3 ]
Gao, Qingchun
Yin, Jian-rui
Pu, Shuxiang
Xie, Changlong
机构
[1] GuangZhou Med Univ, Inst Neurosci, Key Lab Neurogenet & Channelopathies Guangdong Pr, Guangzhou 510260, Guangdong, Peoples R China
[2] GuangZhou Med Univ, Inst Neurosci, Minist Educ China, Guangzhou 510260, Guangdong, Peoples R China
[3] GuangZhou Med Univ, Affiliated Hosp 2, Guangzhou 510260, Guangdong, Peoples R China
基金
中国博士后科学基金;
关键词
Antineutrophil cytoplasmic antibody; Neuromyelitis optica; Multiple sclerosis; NEUROMYELITIS-OPTICA; DIAGNOSTIC-CRITERIA; MULTIPLE-SCLEROSIS; SPECTRUM;
D O I
10.1159/000357681
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We assessed the clinical significance of antineutrophil cytoplasm antibodies (ANCA) in patients with idiopathic inflammatory-demyelinating disease (IIDD). Methods: A consecutive cohort of 269 subjects with IIDD and 595 controls was analyzed retrospectively. Results: Among all subjects, ANCA positivity rates were low [9.5% in a perinuclear pattern (pANCA) and 2.3% in a cytoplasmic pattern (cANCA)]. One of the 117 patients with multiple sclerosis (MS) had cANCA and 2 had pANCA. Ten patients with neuromyelitis optica (NMO; 13.9%) had pANCA and 3 (4.2%) had cANCA. Four patients with recurrent longitudinal extensive transverse myelitis (RLETM; 19.0%) had pANCA and 1 (4.8%) had cANCA. In nnonophasic TM, 22.9% were pANCA seropositive. Among patients with brainstem syndromes, 14.3% were pANCA seropositive. Patients with NMO, RLETM or nnonophasic TM had higher pANCA levels than patients with MS. There was a positive association between spinal cord (SC) lesions and ANCA, and especially between longitudinal extensive transverse myelitis and ANCA. Among anti-aquaporin 4 antibody-positive patients, ANCA-positive patients (n = 16) were older and had higher Expanded Disability Status Scale scores, more antinuclear antibodies, longer SC lesions and fewer brain abnormalities than the ANCA-negative patients (n = 68). In the NMO subgroup, ANCA-positive patients were older and had more antinuclear antibodies and longer SC lesions than ANCA-negative patients. Conclusion: Among the IIDDs, we found a higher occurrence of ANCA in patients with NMO spectrum disorders than in patients with MS. Therefore, ANCA is another interesting marker of autoimmunity in IIDD patients, especially those with anti-aquaporin 4 antibody. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:297 / 303
页数:7
相关论文
共 50 条
  • [41] Serum concentration of CD40L is elevated in inflammatory demyelinating diseases
    Zhong, Xiaonan
    Wang, Honghao
    Ye, Zhiwei
    Qiu, Wei
    Lu, Zhengqi
    Li, Rui
    Shu, Yaqing
    Chang, Yanyu
    Hu, Xueqiang
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 299 : 66 - 69
  • [42] Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: Metaanalysis with a focus on antimyeloperoxidase antibodies
    Choi, HK
    Liu, SM
    Merkel, PA
    Colditz, GA
    Niles, JL
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (07) : 1584 - 1590
  • [43] Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases
    Shin, Joong-Gon
    Kim, Ho Jin
    Park, Byung Lae
    Bae, Joon Seol
    Kim, Lyoung Hyo
    Cheong, Hyun Sub
    Shin, Hyoung Doo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 335 (1-2) : 82 - 88
  • [44] Myelin Oligodendrocyte Glycoprotein as an Autoantigen in Inflammatory Demyelinating Diseases of the Central Nervous System
    Eliseeva, Daria D.
    Zakharova, Maria N.
    BIOCHEMISTRY-MOSCOW, 2023, 88 (04) : 551 - 563
  • [45] Antineutrophil cytoplasmic antibodies in juvenile chronic arthritis
    Bakkaloglu, A
    Ozen, S
    Saatci, U
    Erguven, S
    Topaloglu, R
    Bassoy, Y
    Besbas, N
    CLINICAL RHEUMATOLOGY, 1999, 18 (04) : 304 - 307
  • [46] Clinical value of antineutrophil cytoplasmic antibodies.
    Rus V.
    Handwerger B.S.
    Current Rheumatology Reports, 2000, 2 (5) : 383 - 389
  • [47] Symptomatic epilepsy in inflammatory demyelinating diseases
    N. A. Totolyan
    E. V. Borisova
    A. A. Totolyan
    I. V. Milyukhina
    S. V. Lapin
    A. Yu. Kodzaeva
    L. N. Prakhova
    E. P. Evdoshenko
    E. I. Kairbekova
    A. A. Skoromets
    Neuroscience and Behavioral Physiology, 2012, 42 (3) : 223 - 235
  • [48] Attack-related severity: a key factor in understanding the spectrum of idiopathic inflammatory demyelinating disorders
    Fukazawa, T
    Kikuchi, S
    Niino, M
    Yabe, I
    Miyagishi, R
    Fukaura, H
    Hamada, T
    Tashiro, K
    Sasaki, H
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 225 (1-2) : 71 - 78
  • [49] Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases
    Jiao, Li
    Guo, Shougang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [50] Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
    Spalice, Alberto
    Parisi, Pasquale
    Papetti, Laura
    Nicita, Francesco
    Ursitti, Fabiana
    Del Balzo, Francesca
    Properzi, Enrico
    Verrotti, Alberto
    Ruggieri, Martino
    Iannetti, Paola
    CURRENT NEUROPHARMACOLOGY, 2010, 8 (02) : 135 - 148